Atomo Diagnostics Secures US$6M Investment from The Global Health Investment Fund

New York, NY, January 16, 2016 --(PR.com)-- The investment will support scale up of Atomo’s global health activities, focusing on continued rollout of its award winning AtomoRapid™ HIV test and launch of an affordable HIV self-test offering unmatched performance.

The Global Health Investment Fund (GHIF) announced today that it has provided a US$6 million [A$8.5 million] loan to Atomo Diagnostics (Atomo) to support scale-up of Atomo’s production operations and expansion of commercial activities related to the AtomoRapid™ rapid diagnostic test (RDT) platform. Funds will also be used to commercialise a self-test solution for HIV and other infectious diseases.

Structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, with founding support from Grand Challenges Canada, KfW and SIDA, GHIF focuses its investments in companies addressing key global health challenges. Curt LaBelle, MD, Fund Manager of GHIF said, “We are committed to financing initiatives and technologies that can significantly benefit global health and we are thrilled to support Atomo. We believe that the company’s unique and innovative rapid test solutions support point-of-care testing across a variety of settings and have many exciting applications in both developing world and developed markets.”

As part of the collaborative funding agreement, GHIF and Atomo have made global access commitments to support and facilitate the launch and commercialisation of Atomo’s professional use and self-test products in low and middle-income countries to ensure that they achieve the greatest possible global impact.

Rapid testing in near patient settings is well established and enables quick diagnosis of many types of diseases and conditions using only a small drop of capillary blood from the fingertip. However, current generation lateral flow rapid test kits require multiple test components to perform a test, making them unsuited for use outside of the laboratory. User errors are common with these kits, even among clinicians, and they are generally considered unsuitable for self-testing. Atomo’s RDT solutions replace these multi-component kits with a single integrated user-friendly device, designed specifically to simplify rapid testing and support consumer self-testing.

John Kelly, CEO of Atomo, said, “Our mission has always been to provide the market with products that meet the needs of users. We set out to develop a solution to obsolete the current generation ‘bits in a box’ test kit format, responsible for hundreds of thousands of errors and incorrect diagnoses globally each year. The investment from GHIF not only enables us to scale up our global health activities, it is also a clear endorsement of our innovative AtomoRapid™ technology as a preferred solution for rapid diagnostic testing.”

AtomoRapid™ HIV for professional use was launched in early 2014 and has demonstrated high rates of user preference over existing RDT kits in the field. It has also won a number of prestigious international awards, including ‘Best in Show’ at the 2014 Medical Design Excellence Awards.

Dr. Linda-Gail Bekker, Executive Director of the Desmond Tutu HIV Foundation and President of the International AIDS Society said, "Young South Africans surveyed at the Foundation’s mobile and youth clinics preferred self-testing with the Atomo product over traditional HIV test kits. We urgently need innovation that will facilitate the UNAIDS ambitious goal of 90% of all HIV positive people knowing their status by 2020. GHIF’s investment in Atomo has laid a foundation towards that 90% goal through HIV self-testing.”

As well as supporting tests for HIV, malaria and Ebola, Atomo is finalizing development of an AtomoRapid™ Hepatitis C test on the platform. The company is currently also refining a combination test platform that can diagnose multiple diseases at once, as well as solutions with digital readers and e-health capabilities.

About the Global Health Investment Fund:
GHIF is a private investment fund structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation. The fund received anchor support from Grand Challenges Canada (funded by the Government of Canada), the German Ministry for Economic Cooperation and Development (acting through KfW), the Swedish International Development Cooperation Agency and the Children’s Investment Fund Foundation. The fund’s limited partners also include AXA, GlaxoSmithKline, International Finance Corporation, JPMorgan Chase & Co., Merck, Pfizer Foundation, Storebrand and individual investors.

The fund finances late-stage therapeutics, vaccines and diagnostics for diseases that disproportionately affect low-income populations. Key global health challenges targeted by the fund include malaria, tuberculosis, HIV/AIDS, cholera, maternal and infant mortality and other neglected infectious diseases. The fund and its sponsors believe it offers a novel opportunity to bring about significant improvements in the treatment and prevention of diseases, and reductions in child and maternal mortality, along with the prospect for positive financial returns.

About Atomo Diagnostics:
Atomo is a leading innovator within the point-of-care diagnostic industry, focusing on disruptive solutions that improve usability, safety and accuracy of rapid diagnostic tests (RDTs). The AtomoRapid™ platform supports a wide range of clinical applications and the company is currently commercializing solutions for detection of serious infectious diseases, wellness markers and screening tests for chronic conditions.

Atomo also supplies its platform technologies as an OEM solution, to global diagnostic partners seeking to better meet the needs of their users and enter consumer self-test markets.